Systematic Review Protocol

Oxymetazoline for the treatment of rosacea-associated persistent facial erythema. Systematic review and meta-analysis protocol

Authors:

Geovanna Cárdenas MD, ORCID: 0000-0002-5041-8849
Francisco Novillo DDS, ORCID: 0000-0002-3709-7710
Shuheng Lai DDS, ORCID: 0000-0002-5419-1303
Héctor Fuenzalida, ORCID: 0000-0002-4484-0875
Francisca Verdugo DDS, ORCID: 0000-0003-0199-9744
Gabriel Rada MD, ORCID: 0000-0003-2435-0710

1 Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
2 Fundación Epistemonikos, Santiago, Chile
3 UC Evidence Center, Cochrane Chile Associated Center, Pontificia Universidad Católica de Chile, Santiago, Chile
4 Internal Medicine Department, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Corresponding Author:
Shuheng Lai DDS
Email address: salai@uc.cl
Postal address: Diagonal Paraguay 476, Santiago, Chile.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
ABSTRACT

Objective:
The objective of this systematic review is to assess the impact of oxymetazoline in patients with moderate to severe rosacea.

Data Sources:
We will conduct a comprehensive search in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Lilacs, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, US National Institutes of Health (NIH) and grey literature, to identify all relevant randomized controlled trials regardless of language or publication status (published, unpublished, in press and in progress).

Eligibility criteria for selecting studies and methods:
We will include randomized trials evaluating the effect of oxymetazoline in patients with moderate to severe rosacea. Two reviewers will independently screen each study for eligibility, data extraction, and assess the risk of bias. We will pool the results using meta-analysis and will apply the GRADE [1] system to assess the certainty of the evidence for each outcome.

Ethics and Dissemination:
No ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media.

Protocol and Registration:
This protocol was adapted to the specificities of the question assessed in this review and registered to PROSPERO with the ID CRD42020150262.

Keywords: rosacea, oxymetazoline, systematic review, protocol
INTRODUCTION

Rosacea is a chronic inflammatory skin disease that is characterized by persistent facial erythema, papules, pustules, telangiectasia and recurrent flushing; affecting primarily the cheeks, nose, chin, and forehead [2] [3] [4]. Rosacea affects both women and men equally, with a higher rate amongst people between ages 45 and 60 [5]. Recent findings suggest rosacea might appear also in people of different ethnicity and darker phototype [6].

The pathogenesis of rosacea remains unclear, but genetic factors, overgrowth of commensal organisms, the dysregulation of innate immunity and of the neurovascular system may be involved [7]. Rosacea is characterized by repeated remissions and exacerbations, which results from well described risk factors or triggers, divided into exogenous (ultraviolet radiation exposure, heat, spicy food, stress, alcohol, some medications) and endogenous (hormonal changes, body mass index) [2] [8] [9].

In general, the recommendations for the initial treatment of rosacea includes avoidance of trigger factors, usage of sunscreen, application of moisturizers and gentle cleansing of the whole face. [7] [10]. In the case of persistent facial erythema previously included in the erythematotelangiectatic type of rosacea, brimonidine tartrate, a topical selective α-adrenergic receptor agonist with vasoconstrictive activity has been approved for treatment of persistent facial erythema [7].

Recent clinical trials have been studying the safety and efficacy of oxymetazoline hydrochloride as a new topical to treat persistent erythema in adults. Oxymetazoline is a selective α-adrenoreceptor agonist, and vasoconstrictor of the cutaneous microvasculature [11] [12]. Topical application of oxymetazoline will reduce erythema associated with rosacea through vasoconstrictive effects on the α1-adrenoreceptors [13].

The aim of this systematic review is to provide a rigorous up to date summary of the available evidence on the role of oxymetazoline in the treatment of patients with rosacea-associated persistent facial erythema.
METHODS

Protocol and Registration:
This manuscript complies with the Preferred Reporting Items for Systematic review and Meta-Analysis for reporting systematic reviews and meta-analyses. This protocol was adapted to the specificities of the question assessed in this review and registered to PROSPERO with the ID CRD42020150262.

Eligibility Criteria:

Types of studies
We will include randomized controlled trials (RCTs) meeting our inclusion criteria and reporting useable data. Quasi-randomized trials (QRTs) will not be included. We will exclude studies evaluating the effects on animal models or in vitro conditions.

Types of participants
We will include trials assessing participants aged 18 and above with a diagnosis of moderate to severe erythematotelangiectatic rosacea, defined as ≥grade 3 on the Clinician Erythema Assessment (CEA) and the Subject Self-Assessment for rosacea facial redness (SSA). Participants with another dermatologic condition being treated, systemic diseases and hypersensitivity to oxymetazoline will be excluded.

Types of interventions
We will include trials evaluating the impact of topical application of oxymetazoline for the treatment of rosacea-associated persistent facial erythema. The comparison of interest will be placebo (oxymetazoline hydrochloride cream versus placebo). We will not restrict our criteria to any dosage, duration or timing of administration.

Types of outcome measures
We will not use outcomes as an exclusion criteria during the selection process. Any article meeting all the criteria except for the outcome criterion will be preliminarily included and assessed in full text. We will consider the following outcomes:

Primary outcomes
- Clinician Erythema Assessment (CEA) and the Subject Self-Assessment for rosacea facial redness (SSA)

Secondary outcomes
- Rebound of erythema

Other outcomes
- Total adverse events
Search strategies

Electronic searches
We will conduct a comprehensive search in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Lilacs, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, US National Institutes of Health (NIH) and grey literature, to identify all relevant randomized controlled trials regardless of language or publication status (published, unpublished, in press and in progress). The searches will cover from the inception date of each database until the day before submission.

The following strategy will be used to search in Pubmed/Medline Database. We will adapt it to the syntax of other databases.


Searching other resources
In order to identify articles that might have been missed in the electronic searches, we will do the following:

1. MEDLINE for systematic reviews addressing the same question as our review.
2. In order to find additional literature we will run a Google Scholar search for key terms and authors.
3. We will handsearch reference lists of all included studies and of relevant reviews retrieved by the electronic searching to identify further relevant trial.
4. Authors of included studies will be contacted for any additional published or unpublished data.

Selection of studies
The results of the literature search will be uploaded to the screening software Collaboratron™[14].

In Collaboratron™ [14] two researchers will independently screen the titles and abstracts yielded by the search against the inclusion criteria. We will obtain full-text reports for all potentially eligible studies that appear to meet the inclusion criteria or require further evaluation to decide about their inclusion. The same review authors will assess independently those articles and decide on fulfilment of our inclusion criteria. A third review author will resolve discrepancies in the case of disagreement. Articles retrieved from the screening and included in the review will be recorded in RevMan 5.3 [15]. Excluded trials after full text revision and the primary reason for the decision will be listed.

The selection process will be documented in a in a PRISMA [16] flow diagram adapted for the purpose of this project.
**Data extraction and management**

Using standardized forms, two reviewers will independently extract data from each included study. We will collect the following information: study design, setting, baseline characteristics of patients and study eligibility criteria, details of intervention including dose and duration, number of patients assigned to each group, the outcomes assessed and the time they were measured; number of patients with adverse reactions per treatment group and method used to seek adverse reactions. Losses to follow up, exclusions, and the reasons accordingly. A third reviewer will resolve discrepancies in the case of disagreement.

**Risk of bias assessment**

Risk of bias in included studies will be assessed according to the 'Risk of bias' table, which is the tool recommended by The Cochrane Collaboration [17]. Descriptions and judgements about the following domains for each study will be included: adequacy of sequence generation, allocation concealment, blinding, addressing of incomplete outcome data, likelihood of selective outcome reporting, and other potential sources of bias.

The ‘Risk of bias’ table will be prepared independently by two review authors, with a third review author acting as arbiter. Original study authors will be contacted for further information if one of the review authors requires clarification wherever necessary.

**Measures of treatment effect**

We will report dichotomous outcomes as risk ratio (RR) or odds ratio (OR), with 95% confidence interval (CI) and the continuous outcomes will be reported as mean difference (MD) with 95% CI. Outcomes using different scales will be reported as standardized mean differences (SMD). Then, these results will be displayed on the 'Summary of Findings Table' as mean difference.

**Dealing with missing data**

We will contact the main authors of trials with missing data in order to verify key study characteristics and obtain missing numerical outcome data. If we don't receive any reply, we will analyze the available data. The potential impact of the "missing data" will be addressed in the Discussion section using the analysis of the best and the worst scenario. If no intention to treat (ITT) analysis has been reported or and modified ITT it’s been reported, we will reanalyze the data following intention to treat principles if possible.

**Assessment of Heterogeneity**

Heterogeneity will be quantitatively assessed with a statistical test (Q statistic) and the I² statistic. Statistically significant heterogeneity will be defined as at least one positive test (establishing a cut-off value of P = 0.10 for the Mantel-Haenszel Chi2 test, or values over 50% using the I² statistic)

**Assessment of Reporting Biases**

We will visually assess the presence of publication bias with the use of funnel plots. Evidence of asymmetry will be based on P < 0.10, and present intercepts with 90% CIs. Other reporting biases, including outcome reporting bias, will be evaluated through discrepancies between the registered protocol and the final publication. If we cannot find the record of a study in the WHO International Clinical Trials Registry Platform authors will be contacted for further information.
Data synthesis
Statistical analysis will be performed in accordance with the guidelines for statistical analysis developed by Cochrane [13]. If possible, all studies will be pooled to perform meta-analysis comparing any topical use of oxymetazoline vs placebo for each outcome measure.

When possible, meta-analyses using the random-effects inverse variance model will be carried out to estimate the pooled measure of treatment effect, fixed effects models will be performed to evaluate if findings are not sensitive to choice of analysis. If specific populations or interventions are found to be significantly different, separate meta-analyses will be performed to assess if heterogeneity is explained by some of these, or if a convincing subgroup effect is found. Discrepancies found between random and fixed effects analyses, will be addressed in in the ‘Discussion’.

Subgroup analysis and investigation of heterogeneity
If enough data is available, subgroup analysis will be performed to assess different presentation and concentration of oxymetazoline.

Sensitivity analysis
Sensitivity analyses will be performed to evaluate the impact of the inclusion or exclusion of missing data and the choice of a fixed-effect or random-effects models.

Summary of findings
The certainty of the evidence for all outcomes will be reviewed using the Grading of Recommendations Assessment, Development and Evaluation working group methodology (GRADE Working Group) [1]. Findings for the main outcomes will be summarized in Summary of Findings (SoF) tables.

NOTES

Roles and Contributions
GC conceived the protocol. GC, SL, FN y HF drafted the manuscript, and all other authors contributed to it. The corresponding author is the guarantor and declares that all authors meet authorship criteria and that no other authors meeting the criteria have been omitted.

Competing interests
All authors declare no financial relationships with any organization that might have a real or perceived interest in this work. There are no other relationships or activities that could have influenced the submitted work.

Ethics
As researchers will not access information that could lead to the identification of an individual participant, obtaining ethical approval was waived.

Funding
This project was not commissioned by any organization and did not receive external funding.

PROSPERO Registration
This protocol has been submitted PROSPERO Registration ID: CRD42020150262.
REFERENCES


